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Transparency, Imaginary Worlds and ICER Value Assessments 
Paul C Langley, PhD 
Adjunct Professor, College of Pharmacy, University of Minnesota 
 
Abstract 
The Institute for Clinical and Economic Review (ICER) is seen as offering a credible platform for evaluating the pricing policies for 
pharmaceutical products and devices. Over the past few years ICER has presented a stream of reports, many of which have 
recommended substantial price discounts where the results of a lifetime cost-per-QALY modeling suggests they are out of line with 
notional willingness to pay thresholds and arbitrary budget constraints. At the same time, there have been growing concerns over the 
lack of transparency in the ICER value assessment process, focusing in particular on the refusal by ICER to allow access to its value 
assessment modeling framework. The purpose of this brief commentary is to point out that the position taken by ICER over model 
access is not defensible; the arguments given are specious.  This ongoing refusal undercuts the ICER claim to be independent and the 
credibility of ICER recommendations for price discounting.  The solution is for ICER to commit to a transparent process of value 
assessment, allowing in particular access to its models and for the ICER model to be subject to an independent assessment. At the same 
time, manufacturers and other stakeholders should have access to the model with the opportunity to challenge the model through 
developing model frameworks which they feel better represent product value. This advocacy, it should be noted, does not reflect 
acceptance of the ICER  lifetime cost-per-QALY value assessment framework. Health care decision makers would be better served by a 
value assessment framework that provided short-term credible, evaluable and replicable claims, facilitating meaningful feedback to 
decision makers, and not on the construction of simulated imaginary worlds. 
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Introduction 
The purpose of this commentary is to call into question ICER’s 
apparent reluctance to engage with manufacturers and other 
stakeholders in a transparent and, hopefully, jointly rewarding 
value assessment process. Unlike agencies such as the 
National Institute for Health and Care Excellence (NICE) in the 
UK and the Pharmaceutical Benefits Advisory Committee 
(PBAC) in Australia, transparency for ICER is very much limited 
in respect of the modeled claims for cost-effectiveness. 
Manufacturers and other interested third parties are denied 
access to the actual cost-effectiveness model and are asked to 
take at face value the description of the model, its structure, 
parameter inputs and claims for discounted quality adjusted 
life years (QALYs), years lived (YTD) and direct medical costs.  
Set against notional willingness-to-pay thresholds, and an 
arbitrarily defined budget limit, the value assessment then 
makes claims for necessary downward pricing adjustments for 
a manufacturer’s product; pricing adjustments which can be 
substantial.  
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The lack of transparency in the ICER modeling and review 
process, notably in respect of the cost-effectiveness model has 
been recognized for some time. Concerns have been 
expressed by pharmaceutical manufacturers and industry 
organizations such as the National Pharmaceutical Council.  
The importance of raising the issue of transparency has to be 
seen in the attention given to ICER pricing recommendations. 
This attention to ICER, according to a recent critique of the 
revised ICER value assessment framework,  stems from ‘ …the 
fact that it has surfaced as a credible response to demand 
among the US private payers for health technology assessment 
(HTA) to counter high drug (and device) prices’ 1.  This critique, 
while addressing a number of lingering concerns with the 
updated value assessment framework, does not address the 
question of transparency and access to the underlying cost-
effectiveness model. Also, it should be noted that in accepting 
the health technology assessment (HTA) methodological 
framework in its focus on the construction of lifetime cost-per-
QALY modeled claims, this critique puts to one side the more 
fundamental issues of claims credibility, evaluation, 
replication and feedback. 
 
Whether the status accorded ICER value assessment claims is 
warranted or not is a moot point.  In previous commentaries 
in INNOVATIONS in Pharmacy, the ICER HTA methodology has 
been criticized with the principal argument being that, in 
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following current HTA standards, it fails the standards of 
normal science. The claims made for competing products lack 
credibility because they are neither evaluable nor replicable. 
As part of this ongoing critique four ICER reports have been 
reviewed  2 3 4 5  Most recently, a comprehensive review has 
been presented detailing what are seen as the major 
methodological flows in the construction of ICER lifetime cost-
per-QALY models, with recommendations for abandoning the 
ICER modeling approach in favor of short-term models that 
generate evaluable claims 6. 
 
This latest review of the ICER methodology should be seen in 
the context of some 30 commentaries published in 
INNOVATIONS in Pharmacy since July 2016 7 The focus of these 
commentaries has been to point to the failure of HTAs  to meet 
the standards of normal science 8. This is not an exceptional 
standard as it has been in place since the scientific revolution 
of the 17th century 9. Failure to generate claims that meet 
these standards puts technology assessment at risk of being 
labeled as pseudoscience, sharing a platform with intelligent 
design (in the construction of imaginary worlds) rather than 
natural selection 10 
 
Assumptions and Claims 
The purpose of the present commentary is not to address just 
the question of the scientific status of the ICER HTA 
methodology, but to consider ICER’s attitude to transparency 
in presenting and evaluating value assessment 
recommendations. The argument presented is that the lack of 
transparency in developing and presenting modeled claims, 
together with the absence of a comprehensive review process, 
must cast doubt on the veracity of such claims and, in the 
wider context, the acceptance of recommendations for 
product price discounting.  
 
To give two recent examples: (i) the final evidence report for 
PARP inhibitors in ovarian cancer and (ii)  the final evidence 
report for VMAT2 inhibitors in tardive dyskinesia  11 12 . Both 
reports rely upon long-term or lifetime cost-per-QALY models 
(including cost-per-outcome variants). There is no attempt in 
the modeling to generate evaluable short-term claims. As 
such, if the current HTA standards are accepted, the modeled 
claims and the consequent recommendations for downward 
pricing adjustments have to be taken at face value.  In the case 
of the PARP inhibitors, for example, the use of olaparib for 
maintenance therapy resulted in annual costs of 
approximately $247,600.  At estimated net prices, the cost-
effectiveness of olaparib versus placebo was estimated to be 
approximately $324,000 per QALY and approximately 
$289,000 per life-year gained. Discounts from WAC to reach 
willingness to pay thresholds ranged from 8% to 87% ($50,000 
to $150,000 per QALY). In the case of the VMAT2 inhibitor 
products, modeling, generated an ICER versus placebo for 
valbenazine of $752,080 and an ICER versus placebo for 
deutetrabenazine of $1,100,773. Against an annual WAC for 
valbenazine of $75,789 the value assessment concluded that 
the price should be $11,260; the corresponding figures for 
deutetrabenazine were $90,071 and $9,158 respectively.  
 
Indeed, in looking back to the 1990s in the dawn and halcyon 
days of modeling HTAs, a perennial complaint of health 
systems was the marketing of ‘black box’ claims by 
manufacturers. A model would be presented, typically in a 
simple Excel format, and health systems were invited to punch 
in the relevant parameters to see how the cost-effective the 
product would be. It was intriguing as to how high the 
probability was that the product was cost-effective. The only 
difference is that now we have a more complex black box. 
 
A further issue concerns the absence of a comprehensive, 
published, independent assessment of the ICER model. In 
contrast, when a manufacturer submits a modeled claim 
following the NICE or PBAC guidelines, it is sent to a contracted 
external assessment agency. Electronic versions of the model 
also have to be submitted. In the case of NICE, the External 
Review Group (ERG) provides a full report that may accept the 
model, suggest minor or major changes, or propose an entirely 
new model. The ERG review is then assessed by NICE and the 
results published. It is this degree of transparency and public 
domain access that is essential if ICER is to maintain its status. 
 
Challenging Transparency 
An obvious question is why should ICER abandon its present 
value assessment process? There are three reasons: first, if 
there is to be any confidence in the merits of the ICER value 
assessment, then there needs to be a commitment by ICER to 
full transparency; second, there is always the concern that the 
model may be defective; and third, that even if not judged 
defective in its structure and internal operations, it  is simply 
one of a range of models that could have been developed or 
even reverse engineered to generate countervailing results. 
Models which, for example, could be tailored to a particular 
segment of the US health market.  If the ICER model is just one 
among many, with no particular claim to being in pole position, 
then health systems and other decision makers need to be 
aware of the strengths and shortcomings of the ICER model.  
 
Given these concerns, it seems pointless to delay any model 
access to, say, 12 or 18 months after the release of a final 
report.  If mistakes have been made or pertinent advice on 
clinical appraisals and modeling parameters have been ignored 
or overlooked, it is incumbent upon ICER to remedy these 
issues before final pricing recommendations are made. After 
all, if a recommendation for a price discount against a notional 
willingness-to-pay threshold is subsequently found to be in 
error then the respective manufacturer or manufacturers are, 
presumably, entitled to feel aggrieved given the potential 
revenue stream losses. 
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ICER puts forward two arguments for not releasing copies of 
its cost-effectiveness model 13. Both are specious. The first 
argument is that ‘…. top flight academic health economists and 
their academic institutions require that they retain the 
intellectual property to the executable model and have the 
ability to use it for future academic purposes’. The second 
argument is the ‘very real practical barrier that it is not possible 
to simply hand over a model and expect someone, even 
someone very skilled to know how to dissect or run the model 
without extensive help from the model builder’ with the added 
defense that ‘We have explored this issue with our academic 
modeling network and received consistent guidance that it is 
not feasible to them to assist all stakeholders in this effort 
during the development of the model’. However, there is a 
faint ray of hope: ‘…we will continue to discuss with our 
modelling collaborators the possibility of release of additional 
model information after a suitable “embargo” period to allow 
for academic publication’. By which time possibly, from the 
perspective of the manufacturer launching a new product, any 
damage will have been done. 
 
Without wishing to be unduly cynical regarding whether ICER 
actually wants reviewers to have access to the cost-
effectiveness model, a reasonable response is that, in the 
present case of the PARP inhibitors with the Modelling Group 
at the School of Pharmacy, University of Colorado contracted 
to develop the PARP model, it should be made quite clear that 
they have no rights to restrict access to the model by 
stakeholders and external reviewers on the assumption that  
at some time in the future they may wish to submit the model 
to peer review and possible publication. The same arguments 
apply in the case of the College of Pharmacy Modeling Group 
at the University of Illinois at Chicago where they apparently 
have presumptive rights to the VMAT2 model. If these groups 
wish to meet the standards of normal science, then the model 
access should be a condition of contract as ‘academics for 
hire’. If they wish to publish results, all well and good, but this 
should not be a reason to limit transparency. They are no 
different from other consultants. There is not even the 
defense, in the absence of information supplied by a 
manufacturer, that the model contains commercial 
information. 
 
The second reason is just as ingenuous. We, the potential 
model assessors, don’t apparently have the skills to dissect and 
fully appreciate the complexities of the model, and even if we 
had those skills the developers don’t have time to assist us; the 
we know best defense. Apart from pointing out that the access 
required is to the completed model and not while the model is 
being developed, it is simply nonsense to say that it would not 
be possible for stakeholders such as pharmaceutical 
manufacturers (who have been globally supporting similar 
models for some 20 years in making submissions to NICE and 
other agencies) either to apply their internal skills or to 
contract for them. There are academic review groups in the UK 
(e.g., ScHARR at the University of Sheffield) and in Australia 
(e.g., Adelaide Health Technology Assessment, University of 
Adelaide) who certainly have the skills to assess the model, 
point to deficiencies, suggest improvements or even propose 
an alternative model framework 14 15. There are also a number 
of consulting groups in the private sector with the required 
skills. Given the stakes, there is no doubt that manufacturers 
would find the resources to engage reviewers and place these 
reviews in the public domain.   
 
Exercising the Imagination 
There is no gold standard for constructing a modeled 
imaginary world or simulation. The fact that models may be 
constrained by standards mandated by the assessment 
agency, the NICE reference case is an example, may restrict the 
available options, but still gives consultants and others 
considerable latitude in model design. Also, the fact that 
modeled claims typically take a natural or lifetime course of 
disease, also gives additional latitude in the choice of 
assumptions. If claims are not evaluable, as would be the case 
in a lifetime cost-per-QALY models, then this eliminates an 
important constraint on the exercise of the modeler’s 
imagination.  
 
In the absence of a gold standard, particularly for a one-size-
fits-all imaginary world, means that model builders have few 
constraints. Certainly, they are constrained by evidence for the 
course of the disease and target patient characteristics for the 
index intervention. Beyond that they have a range of options 
for the structure of the model, application of some variant of 
the ubiquitous Markov framework, the choice of disease 
progression staging, selecting transition probabilities, the 
choice of inputs and the values or parameters attached to 
those inputs. Indeed, it is entirely possible, and 
understandable, that those underwriting a model may insist 
that the model put the product in question in the most 
favorable light. After all, if formulary approval, a favorable tier 
placement and a premium price are the objectives, then there 
is little doubt that such a result will be forthcoming. The model 
is fulfilling its role as an advocate for the product. In the same 
vein, product competitors may underwrite models that put 
their product in the best light against competitor models.   
 
Whether or not the primary purpose of modeling cost-
effectiveness claims is to advocate a favorable outcome for a 
product, there is a role for independent assessors. This is 
recognized by NICE and the PBAC. This does not mean, 
however, that groups such as ICER who put themselves 
forward as independent arbiters should not meet the same 
standards. This is a particular concern in the US market where 
target populations for PARP inhibitors or more recently VMAT2 
inhibitors are dispersed across a fragmented health care 
delivery system. ICER in this context is no better than a 
consulting group commissioned by a manufacturer to prepare 
a dossier for submission following, for example, the Academy 
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of Managed Care Pharmacy (AMCP) Format for formulary 
submissions16. At least the AMCP has the good grace to 
suggest that an electronic version of the model should be 
presented. Indeed, in the case of the US, it could be argued 
that a ‘one size fits all’ model, even if it allows manipulation of 
key parameters or develops a range of treatment and outcome 
scenarios, with the inevitable defense of using sensitivity 
analysis and probabilistic parameters to capture ‘uncertainty’, 
has to give way to models targeted to patients in a range of 
health delivery systems. Access to an electronic model would 
be a necessary first step to ensuring that, to some extent at 
least, non-evaluable model claims were consistent with target 
patient characteristics and the decision making environment.  
 
In the last resort, however, there is no ‘gold standard model’. 
As noted, in the absence of evaluable credible claims, even the 
most ‘realistic’ model fails the standards of normal science. 
This is apart from the obvious point that it is impossible to 
grade models by their degree of ‘realism’, although this 
appears to be the intent of model builders. Looking forward 20 
– 30 years in modeled claims certainly stretches credulity. 
There is no feedback to decision makers on the outcomes 
achieved in treatment practice. There is no possibility of 
replicating claims assessments across diverse health care 
delivery systems. We may be able to exercise our imaginations 
in developing models but, in the absence of platforms for 
evaluating credible claims, the exercise is, in the last resort, 
essentially a waste of time and resources.  
 
Nonetheless, constructing lifetime-cost-per-QALY simulations 
is a major preoccupation in HTA. This stems, in large part, from 
the standards for formulary submission either recommended 
or mandated by professional associations or by health system 
decision makers. The AMCP formulary submission format and 
the good research practices recommended by the 
International Society for Pharmacoeconomics and Outcomes 
Research would be in the former category, the reference case 
required by NICE would be in the latter 17 18. Leading textbooks 
further add their weight to constructing imaginary worlds 19. 
 
The response to the challenge of constructing imaginary 
worlds has been overwhelming with literally thousands of 
models developed, published and presented to journals and 
assessment agencies over the past 30 years. Apart from the 
fact that few of these models have generated credible and 
evaluable claims, they continue to be a bread and butter 
product for academic centers and consulting groups. 
Constructing lifetime imaginary worlds has the obvious appeal 
that the claims are immune to failure with the result that the 
only challenge can come from a review of the model itself in 
the choice of model structure, the choice and measurement of 
input parameters and the further choice of model scenarios. 
 
These standards are well entrenched and, as noted in a 
previous review of the latest revision to the Canadian 
guidelines, it is recognized by assessment agencies that they 
are not intended to meet the standards of normal science 20 21. 
Rather than supporting a process of what Popper would 
describe as conjecture and refutation in improving our 
understanding of cost-outcome models to generate credible, 
evaluable and replicable cost-effectiveness claims, the 
response as stated in the latest version of the Canadian 
guidelines is to acknowledge: Economic evaluations are 
designed to inform decisions. As such they are distinct from 
conventional research activities, which are designed to test 
hypotheses 22. Whether decision makers wish to be informed 
by the construction of imaginary worlds is a moot point. 
 
Care also has to be taken in not being overly-imaginative in 
constructing lifetime cost-per-QALY models. All too often the 
evidence base is simply too weak to support even the attempt 
at modeling. Unfortunately, the natural impulse is for authors 
to persevere, defending their decision by a brief mea culpa 
statement of data limitations as if that absolved them from any 
responsibility that their conclusions might actually be acted 
on. While, as noted, a model should not be judged on the 
realism of its assumptions, the critical issue is one of 
experimentation and observation. Even so, it is always worth 
noting the assumptions supporting  the model. In the case of  
the VMAT2 inhibitors value assessment there is an extensive 
list of assumptions made to support the base case model. 
These include assumptions regarding long-term response to 
treatment, assumptions regarding discontinuation of therapy, 
assumptions regarding prior treatment before entering the 
model and assumptions regarding primary care visits to for 
responders/non-responders in the long term (p.ES16). Equally 
importantly, it is always worth noting the limitations 
acknowledged by the model builder. Again, in the case of the 
VMAT2 inhibitors these include: (i) effectiveness data that 
were based on limited intermediate measures from clinical 
trials; (ii) tardive dyskinesia severity measures that do not 
accurately reflect disease burden on overall quality of life; (iii) 
lack of data on discontinuation of  target modeled  medication 
due to adverse events beyond the first year; (iv) lack of robust 
data on non-drug costs of tardive dyskinesia; and (v) inability 
to include sub-populations who may differ from the average 
tardive dyskinesia patient due to a lack of data (p. ES23). 
 
In the absence of access to the model itself, it is impossible to 
judge the impact of these assumptions/limitations on the non-
evaluable model claims. This again should cast doubts on the 
exercise and its recommendations. Perhaps a more realistic 
evaluation of the evidence in terms of  recommendations for  
meeting evidence gaps in the clinical profile of competing 
products together with the design of protocols to support  
credible and evaluable short-term claims might be a more 
viable and meaningful option.  
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Quis custodiet ipsos custodes 23 
If we accept, for present purposes, that non-evaluable, 
assumption-based, imaginative lifetime cost-per-QALY claims 
have a positive contribution to make as ‘information’ to health 
system decision makers, then we should, presumably, 
endeavor to seek assurance that the model itself meets some 
standard for assessing the construct.  
 
Unlike the review process mandated by NICE in the UK and the 
PBAC in Australia, ICER has no required formal process 
whereby its clinical evaluation and cost-effectiveness model is 
subject to independent professional scrutiny. The NICE Single 
Technology Appraisal Process (STA) is a good example of the 
level of transparency and engagement that should be  required 
24.  If ICER was to commit to a similar process of external review 
then there are a number of elements in the process of 
independent assessment that should be met.  
 
First, before any engagement between stakeholders and ICER 
is initiated, in particular the manufacturers whose products 
are under scrutiny, ICER should agree the nominated agency 
that is to undertake an independent assessment of the 
modeled case. The academic group contracted by ICER to build 
the model should be informed of the choice made and should 
declare they have no conflict of interest in respect of the 
assessment group. . The contractors for the value assessment 
report will be advised that their value assessment, to include 
their clinical assessment of the products or devices under 
review, their proposed decision framework, modeling 
assumptions and inputs and the various pricing scenarios will 
all be subject to review. They will also be advised that all value 
assessment reviews, unless there is commercially confidential 
information, will be posted to an ICER public access website.  
 
Second, it is important that the modeled value assessment 
should be put in the context of previous modeled assessments 
that have been undertaken by other agencies (e.g., NICE, 
PBAC) or presented as peer reviewed publications. noting 
which previous modeled cases have been supported by 
interested manufacturers. A detailed assessment of these 
previous modeled claims should be presented, in particular 
models claims that have generated potentially evaluable and 
replicable claims (and whether these have been subject to 
empirical evaluation). While the details of these models will 
obviously differ (e.g., unit prices of the target pharmaceutical 
products or devices), the substance of the clinical assessment 
and the intent of the modeling (e.g., lifetime QALY estimates) 
will often be similar. This material needs to be reviewed with 
details on any differences in clinical claims with model 
frameworks described and compared to the model framework 
developed for the ICER assessment.  
 
Third, the agency selected for the independent review, will 
have been advised that their assessment including 
recommendations will be posted to the public domain. At the 
same time, by request, any stakeholder to the ICER value 
assessment process should have access rights to the model 
and all supporting materials (e.g., copies of referenced 
papers).  
 
Fourth, there should be agreement between ICER and 
stakeholders on a set of ‘key questions’ that the independent 
assessment agency should be asked to address. This 
‘assessment template’ should, first and foremost, address the 
issue of the extent to which the modeled claims meet the 
standards of normal science: are the modeled claims 
presented credible, evaluable and replicable? Does the model 
contracted by ICER provide for feedback to formulary 
committees so that they can judge the relative clinical and 
cost-outcomes claims for the competing products? If not, then 
the assessor should be asked to categorize the model as one 
that is ‘for information only’ and not one that meets the 
standards of normal science. As such, it would sit alongside 
other imaginary modeled worlds with the assessor pointing to 
the differences between these various ‘worlds’ in choice of 
model framework and the assumptions built into the model. 
Particular note might be taken of the utility estimates and 
whether these are considered as robust. 
 
It should be noted that there are modeling review templates 
that have been proposed. These include the CHEERS 
(Consolidated Health Economic Evaluation Reporting 
Standards) and the more recent PROST (Protocol Standards) 
checklist 25 26. The CHEERS checklist was designed to optimize 
the reporting of conventional health economic evaluations, to 
include both the reporting of evaluations alongside clinical 
trials as well a non-evaluable lifetime cost-per-QALY models. 
The PROST checklist is focused on evaluating and replicating 
evaluable claims through prospective studies where patients 
are tracked from existing data sources as well as prospective 
observational studies. It is an integral part of the proposed 
Minnesota Guidelines for Formulary Evaluation 27. The PROST 
checklist is not intended to be applied to an assessment of 
modeled imaginary worlds where there is no intention of 
presenting claims that can be assessed and reported to 
formulary committees. The latest version of PROST includes 
checklist items for evaluating next generation sequencing 
(NGS) claims  28 . It should also be pointed out that the PROST 
template requires manufacturers to present a protocol for 
assessing their claims in treatment practice. Obviously, in the 
case of ICER, it is impossible to put forward a protocol to test 
claims that are generated by lifetime cost-per-QALY models! 
 
Fifth, as stakeholders with a major interest in modeled claims 
for efficacy and recommendations for pricing, manufacturers 
should be given the opportunity for presenting their own 
modeled claims. These models may range from those intended 
to generate credible, evaluable and replicable claims for short-
term assessment and feedback, to models which adopt a long-
term or lifetime cost-per-QALY framework, intended as 
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‘information only’ offerings. These models may be constructed 
by consultant or other groups under contract with the 
manufacturer. Again, these should be posted to the public 
domain. This should be relatively straightforward given their 
likely prior experience in submissions to health technology 
agencies. The intent here, of course, is to point out to health 
care decision makers that once the standards of normal 
science are put to one side, then, from the perspective of 
constructing any number of competing claims from competing 
imaginary worlds, the only constraint is the lack of imagination 
of the model builders and their willingness to embrace 
‘realistic’ assumptions. 
 
Sixth, there needs to be ample time for responses to the ICER 
model. There should not be a rush to present claims. Rather 
there needs to be time (as noted below) for a considered 
response. Three to four months would be reasonable. 
 
Finally, given ICER is the initiator of this review process and its 
intent in formulating pricing recommendations, ICER should 
present responses to the results of the review process. These 
should be posted on-line, with further responses or rebuttals 
by stakeholders also placed in the public domain. ICER should 
then be in a position to complete a final value assessment 
report.   
 
If ICER is not prepared to engage in this process to support a 
more comprehensive and transparent process of value 
assessment, then it may be incumbent upon an outside group 
or, indeed, individual manufacturers, to establish a website 
where assessments of the respective ICER reports are posted.  
These could include: 
 
• an assessment of the model with independent 
reviews of  the model in a standard template format 
(based on requested access to the electronic version 
of the model)  
• outcomes from alternative model structures (to 
include a systematic review) 
• protocols for short-term claims assessment for 
evaluation and feedback to formulary committees 
• assessments by interested manufacturers and 
interested third parties (e.g., health system 
formularies) 
• responses to questions directed to ICER and outside 
groups responsible for the modeling 
Conclusions 
ICER’s apparent unwillingness to engage in a comprehensive 
and meaningful assessment of the structure and assumptions 
of their cost-effectiveness model by third parties is 
unacceptable. Put bluntly, unless ICER is prepared to meet the 
standards for independent review set by agencies such as NICE 
and the PBAC, then any conclusions drawn from the model 
regarding pricing adjustments and budget impact must be put 
to one side. While this may be seen as an unnecessarily harsh 
conclusion, the fact that ICER has placed itself as an 
independent arbiter of value assessments, free of any 
obligations to manufacturers and health system decision 
makers, requires an independent and transparent review 
process. This is not intended to cast aspersions on the 
academic groups contracted with the ICER to construct 
models. Rather, experience with model reviews in the UK  and 
Australia points to the leeway possible in structuring models 
and choice of assumptions in the construction of these 
imaginary worlds. 
 
Insisting on an independent assessment of ICER models, the 
cost-per-QALY imaginary world paradigm, is not to endorse the 
present methodology. As noted in previous commentaries, 
these constructs fail to meet the standards of normal science. 
This alone would be sufficient grounds to reject the 
methodology and consequent value assessments. Even, 
however, if ICER was prepared to abandon their commitment 
to what has been described in previous reviews of ICER as 
pseudoscience and commit to modeling frameworks designed 
to generate credible and evaluable claims, these should also 
be subject to independent review. The difference here, 
however, is that that the review would extend to the 
evaluation of protocols proposed by ICER to evaluate claims 
and to track and report the results of the application of these 
protocols in target patient populations. ICER would be 
accepting the role of hypothesis testing. 
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